Skip to main content

Table 2 The concentrations at which 50 and 90 % of infections are prevented under the various conditions of copper phthalocyanine sulfate (CuPcS) exposure: HIV pre-treated with CuPcS; peripheral blood mononuclear cells (PBMC) pre-treated with CuPcS; simultaneous addition of HIV, PBMCs, and CuPcS; and pre-incubation of HIV and PBMCs with subsequent addition of CuPcS

From: In vitro antiretroviral activity and in vivo toxicity of the potential topical microbicide copper phthalocyanine sulfate

CuPcS Inhibition of HIV-1BAL Infection of PBMCs

 

EC50 μg/ml

EC90 μg/ml

HIV pre-treated

53.31

184.7

PBMCs pre-treated

42.96

147.2

CuPcS added post-infection

26.11

215.3

Combined addition

54.72

186.7

Pre (100 μg/mL)- and post-treatment

Undefined

Undefined